Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
67.75 USD | -0.75% | +2.36% | +0.59% |
01:19pm | ASTRAZENECA : Deutsche Bank reiterates its Sell rating | ZD |
Mar. 27 | AstraZeneca CEO Sees No Impact from Biosecure Act | MT |
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Sales forecast by analysts have been recently revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Weaknesses
- The company benefits from high valuations in earnings multiples.
- The company's enterprise value to sales, at 3.6 times its current sales, is high.
- The company appears highly valued given the size of its balance sheet.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+0.59% | 210B | - | ||
+33.46% | 701B | C+ | ||
+26.24% | 571B | B | ||
+0.93% | 381B | C+ | ||
+21.03% | 334B | B- | ||
+17.51% | 319B | C+ | ||
+2.95% | 210B | B- | ||
-6.05% | 201B | A+ | ||
-3.61% | 157B | C+ | ||
-1.28% | 153B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock
- Equities
- Stock AstraZeneca PLC
- Stock AstraZeneca PLC - Nasdaq
- Ratings AstraZeneca PLC